Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2020-09-08

FDA Approved: GABAPENTIN — Supplemental Application (Exelan Pharmaceuticals, Inc.)

View source ↗

Summary

FDA approved a supplemental application for gabapentin from Exelan Pharmaceuticals, Inc. under an ANDA.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Gabapentin (Gabapentin)

Snippet

SUPPL AP for GABAPENTIN (GABAPENTIN)